Table 4.
Predictors of local control, overall and colostomy-free survival in univariate analysis (n= 51)
| |
Overall survival |
Locoregional relapse-free survival |
Colostomy-free survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | CI 95% | p-value | HR | CI 95% | p-value | HR | CI 95% | p-value | |
|
WHO |
|
|
|
|
|
|
|
|
|
|
0 |
1 |
[0.99-7.17] |
0.053 |
1 |
[0.83-5.64] |
0.115 |
1 |
[1.3-8.07] |
0.012 |
|
1/2 |
2.66 |
|
|
2.16 |
|
|
3.24 |
|
|
|
T Stage |
|
|
|
|
|
|
|
|
|
|
T1/T2/in situ |
1 |
[0.45-3.42] |
0.684 |
1 |
[0.38-2.64] |
1 |
1 |
[0.44-2.73] |
0.846 |
|
T3/T4 |
1.23 |
|
|
1 |
|
|
1.1 |
|
|
|
N Stage |
|
|
|
|
|
|
|
|
|
|
N0 |
1 |
[0.95-7.5] |
0.062 |
1 |
[0.97-7.46] |
0.057 |
1 |
[1.04-6.91] |
0.042 |
|
N1/N2/N3 |
2.67 |
|
|
2.69 |
|
|
2.68 |
|
|
|
Histology |
|
|
|
|
|
|
|
|
|
|
Squamous cell cancer other |
1 0.86 |
[0.2-3.82] |
0.846 |
1 0.83 |
[0.19-3.65] |
0.809 |
1 0.68 |
[0.16-2.97] |
0.612 |
|
Treatment duration |
|
|
|
|
|
|
|
|
|
|
<56 days |
1 |
[0.26-1.96] |
0.511 |
1 |
[0.23-1.60] |
0.317 |
1 |
[0.23-1.49] |
0.262 |
|
>56 days |
0.71 |
|
|
0.61 |
|
|
0.59 |
|
|
|
Total dose |
|
|
|
|
|
|
|
|
|
|
<50 Gy |
1 |
[0.11-6.47] |
0.874 |
1 |
[0.14-8.09] |
0.951 |
1 |
[0.04-0.88] |
0.033 |
|
>50 Gy |
0.85 |
|
|
1.07 |
|
|
0.19 |
|
|
|
Technique |
|
|
|
|
|
|
|
|
|
|
3D-CRT |
1 |
[0.46-3.94] |
0.580 |
1 |
[0.55-3.98] |
0.431 |
1 |
[0.81-5.66] |
0.125 |
|
IMRT |
1.35 |
|
|
1.48 |
|
|
2.14 |
|
|
|
Treatment breaks for toxicity |
|
|
|
|
|
|
|
|
|
|
Yes |
1 |
[0.23-4.46] |
0.996 |
1 |
[0.37-4.56] |
0.680 |
1 |
[0.16-2.96] |
0.607 |
|
No |
1 |
|
|
1.3 |
|
|
0.68 |
|
|
|
Planned gap |
|
|
|
|
|
|
|
|
|
|
Yes |
1 |
[0.29-3.17] |
0.943 |
1 |
[0.3-2.4] |
0.765 |
1 |
[0.37-3.17] |
0.882 |
|
No |
0.96 |
|
|
0.85 |
|
|
1.08 |
|
|
|
Pelvic radiotherapy |
|
|
|
|
|
|
|
|
|
|
Yes |
1 |
[0.34-3.33] |
0.905 |
1 |
[0.44-5.35] |
0.501 |
1 |
[0.45-4.1] |
0.587 |
| No | 1.07 | 1.54 | 1.36 | ||||||